1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Cosmo Pharmaceuticals N.V.
  6. News
  7. Summary
    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
Real-time Estimate Cboe Europe  -  05/19 07:30:11 am EDT
50.60 CHF   -0.98%
05/03Cosmo Pharmaceuticals, Medtronic Sign Global Distribution Deal for Eleview
MT
05/03Cosmo announces expanding the agreement with medtronic for eleview(r) to all countries except canada
EQ
05/03Cosmo Pharmaceuticals N.V. Announces Expanding the Agreement with Medtronic for Eleview® to All Countries Except Canada
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cosmo Closes Public Exchange Offer For Cassiopea After Amassing 97% Stake

12/17/2021 | 01:14am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
COSMO PHARMACEUTICALS N.V. -0.78% 50.7 Delayed Quote.-22.10%
All news about COSMO PHARMACEUTICALS N.V.
05/03Cosmo Pharmaceuticals, Medtronic Sign Global Distribution Deal for Eleview
MT
05/03Cosmo announces expanding the agreement with medtronic for eleview(r) to all countries ..
EQ
05/03Cosmo Pharmaceuticals N.V. Announces Expanding the Agreement with Medtronic for Eleview..
CI
05/02COSMO PHARMACEUTICALS N : Notification of number of shares
PU
04/15COSMO PHARMACEUTICALS N : Convening notice
PU
04/15COSMO PHARMACEUTICALS N : Explanatory notes
PU
04/15COSMO PHARMACEUTICALS N : Notification of number of shares
PU
04/15COSMO PHARMACEUTICALS N : Proposed Amendments to the Remuneration Policy
PU
04/15COSMO PHARMACEUTICALS N : Written proxy
PU
03/23Cosmo pharmaceuticals - full-year results 2021, confirms beating guidance
AQ
More news
Analyst Recommendations on COSMO PHARMACEUTICALS N.V.
More recommendations
Financials
Sales 2022 91,4 M 95,9 M 95,9 M
Net income 2022 17,6 M 18,4 M 18,4 M
Net cash 2022 41,6 M 43,7 M 43,7 M
P/E ratio 2022 47,4x
Yield 2022 0,73%
Capitalization 823 M 864 M 864 M
EV / Sales 2022 8,55x
EV / Sales 2023 6,14x
Nbr of Employees 290
Free-Float 52,8%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 49,28 €
Average target price 92,51 €
Spread / Average Target 87,7%
EPS Revisions
Managers and Directors
Alessandro Della Chà Executive Director
Niall Donnelly Chief Financial Officer
Mauro Severino Ajani Director
Davide Malavasi Director-Qualified Person & Technical
Nhan Ngo Dinh Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
COSMO PHARMACEUTICALS N.V.-22.10%864
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329